Targetable Gene Rearrangements in Advanced Lung Cancer: Optimized Testing and Management

home / insights / targetable-gene-rearrangements-in-advanced-lung-cancer-optimized-testing-and-management

This OncLive Insights features 3 experts who share their thoughts on how the treatment landscape of advanced NSCLC is evolving through use of comprehensive genetic sequencing to identify actionable biomarkers. They summarize how novel therapeutics which target driver alterations in ALK, ROS, RET, or NTRK can be leveraged to personalize and optimize management of advanced NSCLC, ultimately improving survival outcomes.

EP. 1: Overview of Targeted Therapies, Improved Outcomes, and Unmet Needs in Advanced NSCLC

Benjamin Levy, MD;Mark A. Socinski, MD;Stephen Liu, MD

October 11th 2021

An increased understanding of driver gene alterations in advanced non–small cell lung cancer (NSCLC) has led to the development of targeted therapies that offer improved patient outcomes. Ben Levy, MD; Mark A. Socinski, MD; and Stephen Liu, MD, share their thoughts on the emerging treatment landscape and remaining unmet needs.

EP. 2: Testing for Gene Alterations and Protein Expression in Advanced NSCLC

Benjamin Levy, MD;Mark A. Socinski, MD;Stephen Liu, MD

October 11th 2021

Ben Levy, Mark Socinski, and Stephen Liu explain the various types of genetic alterations and protein expressions that are targetable in NSCLC and the crucial role of comprehensive genetic testing at the time of diagnosis and at the time of disease progression.

EP. 3: ALK Alterations in Advanced NSCLC

Benjamin Levy, MD;Mark A. Socinski, MD;Stephen Liu, MD

October 18th 2021

Ben Levy, Mark Socinski, and Stephen Liu explain the role of an ALK alteration in NSCLC and its value as a targetable biomarker.

EP. 4: Clinical Management of ALK+ Advanced NSCLC

Benjamin Levy, MD;Mark A. Socinski, MD;Stephen Liu, MD

October 18th 2021

Ben Levy, Mark Socinski, and Stephen Liu describe the current treatment options for patients with ALK+ NSCLC. They also summarize recent clinical data for ALK inhibitors.

EP. 5: ROS1 Alterations in Advanced NSCLC

Benjamin Levy, MD;Mark A. Socinski, MD;Stephen Liu, MD

October 25th 2021

Ben Levy, Mark Socinski, and Stephen Liu explain the role of a ROS1 alteration in NSCLC and its value as a targetable biomarker.

EP. 6: Clinical Management of ROS1+ Advanced NSCLC

Benjamin Levy, MD;Mark A. Socinski, MD;Stephen Liu, MD

October 25th 2021

Ben Levy, Mark Socinski, and Stephen Liu describe the current treatment options for patients with ROS1+ NSCLC. They also summarize recent clinical data for agents that target ROS1.

EP. 7: RET Alterations in Advanced NSCLC

Benjamin Levy, MD;Mark A. Socinski, MD;Stephen Liu, MD

November 1st 2021

Ben Levy, Mark Socinski, and Stephen Liu explain the role of a RET alteration in NSCLC and its value as a targetable biomarker.

EP. 8: Clinical Management of RET+ Advanced NSCLC

Benjamin Levy, MD;Mark A. Socinski, MD;Stephen Liu, MD

November 1st 2021

Mark Socinski and Stephen Liu describe the current treatment options for patients with RET+ NSCLC. They also summarize recent clinical data for agents that target RET.

EP. 9: Clinical Management of NTRK+ Advanced NSCLC

Benjamin Levy, MD;Mark A. Socinski, MD;Stephen Liu, MD

November 8th 2021

Ben Levy, Mark Socinski, and Stephen Liu describe the current treatment options for patients with NTRK+ NSCLC. They also summarize recent clinical data for agents that target NTRK.